Novartis to answer U.S. Senate demand for data manipulation details
Reuters
Published Aug 19, 2019 03:21AM ET
Novartis to answer U.S. Senate demand for data manipulation details
ZURICH (Reuters) - Novartis (S:NOVN) plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker's decision to delay informing regulators until after the treatment's approval.
"We are planning to respond but we haven't submitted yet," a spokesman said on Monday.
U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.
Novartis, which won approval for Zolgensma in May -- more than a month before it told the Food and Drug Administration of the alleged data fraud -- has terminated several scientists amid an internal investigation.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.